Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience.

---

Atıf İçin Kopyala

Kaya B., Barutcu Atas D., Tukenmez Tigen E., Asicioglu E., Arikan H., Tuglular S., ...Daha Fazla

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, cilt.20, sa.2, ss.143-149, 2022 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 20 Sayı: 2
• Basım Tarihi: 2022
• Doi Numarası: 10.6002/ect.2021.0252
• Dergi Adı: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
• Sayfa Sayıları: ss.143-149
• Anahtar Kelimeler: COVID-19 pandemic, Kidney transplantation, Severe acute respiratory syndrome coronavirus 2, PATIENT, DISEASE
• Marmara Üniversitesi Adresli: Evet

Özet

Objectives: Kidney transplant recipients are among the high-risk groups for severe COVID-19. To date, no specific antiviral agent has proved uniformly effective against SARS-CoV-2. Favipiravir, the recommended drug by the Turkish Ministry of Health, was uniformly supplied to all patients diagnosed with COVID-19 by a positive nasopharyngeal swab polymerase chain reaction test. The aim of our study was to retrospectively compare our kidney transplant recipients treated with favipiravir who developed COVID-19 infection versus those not treated with favipiravir during the clinical course of the disease, with a special emphasis on the occurrence of side effects and adverse events.